14-day Premium Trial Subscription Try For FreeGet Free
Radcliffe Capital Management, L.P. (Trades, Portfolio), a prominent investment firm, recently made a significant acquisition in the stock market.
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
NuVasive, Inc. (NASDAQ:NUVA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Chris Barry - Chief Executive Officer
NuVasive (NUVA) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.54 per share a year ago.
Globus Medical caught headlines after announcing the NuVasive merger. Investors have wiped out considerable equity post-announcement, but the worst may be now priced in.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

New Strong Buy Stocks for April 26th

09:08am, Wednesday, 26'th Apr 2023
EGY, MSGS, NUVA, NWG and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on April 26, 2022.
Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). But which of these two stocks is more attractive to value investors?
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?
NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.
According to NuVasive (NUVA), the combined company is set to have an advanced commercial scale and portfolio of clinically proven solutions.

Bear of the Day: NuVasive (NUVA)

07:32am, Thursday, 02'nd Mar 2023
Softer results for spinal surgery innovator plus questionable merger have dropped estimates and shares
SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integr
Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.
NuVasive, Inc. (NASDAQ:NUVA ) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Juliet Cunningham - VP, IR Christopher Barry - CEO & Director Matthew Harbaugh - EVP &
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE